前沿生物(688221) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥11,911,271, representing a 110.06% increase compared to the same period last year[5]. - The net profit attributable to shareholders was -¥75,708,310, with a basic and diluted earnings per share of -¥0.20[5]. - Net loss for Q1 2023 was ¥75,708,310.01, compared to a net loss of ¥59,241,597.75 in Q1 2022, indicating a deterioration in financial performance[24]. - Comprehensive loss for Q1 2023 totaled ¥75,720,718.28, compared to a comprehensive loss of ¥59,246,518.93 in Q1 2022[24]. - Basic and diluted earnings per share for Q1 2023 were both -¥0.20, compared to -¥0.16 in Q1 2022[24]. Revenue and Sales - The company achieved a revenue of RMB 11.91 million in Q1 2023, representing a year-on-year growth of 110%, primarily driven by sales of its core product, Aikening[14]. - Total operating revenue for Q1 2023 reached ¥11,911,271, an increase of 110.5% compared to ¥5,670,338.94 in Q1 2022[22]. - Cash received from sales of goods and services in Q1 2023 was ¥12,457,781.93, a decrease from ¥13,412,566.02 in Q1 2022[27]. Operating Costs and Expenses - The company experienced a 60.14% increase in operating costs, primarily due to increased sales volume[9]. - Total operating costs for Q1 2023 were ¥93,802,116.07, up from ¥73,476,784.35 in Q1 2022, representing a 27.7% increase[23]. - Research and development expenses totaled ¥44,347,571, accounting for 372.32% of revenue, a decrease of 259.48 percentage points year-on-year[6]. - Research and development expenses for Q1 2023 amounted to ¥44,347,571.68, an increase of 23.6% from ¥35,825,300.07 in Q1 2022[23]. Cash Flow - Cash flow from operating activities was -¥68,647,762.96[5]. - The net cash flow from operating activities was -68,647,762.96, compared to -34,410,228.06 in the previous year, indicating a significant decline in operational cash generation[28]. - Total cash outflow from operating activities was 103,800,954.73, compared to 94,833,107.17, showing an increase in operational expenses[28]. - Cash received from other operating activities was 16,967,529.79, compared to 32,298,557.04, indicating a decline in operational cash inflows[28]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,333,847,061, a decrease of 3.19% from the end of the previous year[6]. - Total liabilities as of Q1 2023 were ¥737,928,067.87, slightly down from ¥739,409,818.25 in Q1 2022[19]. - Total equity attributable to shareholders of the parent company was ¥1,595,918,993.14, down from ¥1,671,449,391.84 in Q1 2022[19]. - Non-current liabilities totaled ¥469,997,166.21 in Q1 2023, an increase from ¥462,179,699.47 in Q1 2022[19]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,931[11]. - The top shareholder, Jianmu Pharmaceutical Co., Ltd., holds 18.86% of the shares, totaling 70,638,750 shares[11]. Product and Market Development - The company has established coverage in over 280 HIV treatment hospitals and more than 150 DTP pharmacies across 28 provinces in China by the end of the reporting period[14]. - The company hosted a national academic seminar on "Personalized Antiviral Treatment," where over 70 experts shared clinical applications and patient benefits of Aikening[15]. - Aikening's invention patent received the "China Patent Gold Award," recognizing its significance in the field of AIDS prevention and control in China[15]. - The company is actively promoting Aikening for outpatient treatment reimbursement to enhance long-term medication affordability[14]. Cash and Inventory - The company's cash and cash equivalents stood at RMB 592.18 million, an increase from RMB 550.89 million at the end of 2022[17]. - The company's inventory increased to RMB 71.50 million from RMB 55.61 million at the end of 2022[18]. - Short-term borrowings rose to RMB 175.16 million from RMB 110.64 million at the end of 2022[18]. - Short-term borrowings increased by 58.32%, attributed to additional borrowing[9].